Spots Global Cancer Trial Database for Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration
Official Title: A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced Non-Small Cell Lung Cancer With an FGFR Alteration Who Progressed on Previous Therapy (FIGHT 210)
Study ID: NCT05253807
Conditions
Interventions
Study Description
Brief Summary: This is an open-label, single arm study to study the safety, efficacy and tolerability of Pemigatinib when used on participants with squamous or nonsquamous NSCLC with a documented FGFR1-3 mutations or fusions/rearrangement who have progressed on prior therapies and have no available standard treatment options
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Valkyrie Clinical Trials, Los Angeles, California, United States
Florida Cancer Specialists & Research Institute, Fort Myers, Florida, United States
Miami Cancer Institute, Miami, Florida, United States
Memorial Healthcare System, Pembroke Pines, Florida, United States
University of Kentucky Hospital, Lexington, Kentucky, United States
Spoknwrd Clinical Trials Inc., Easton, Pennsylvania, United States
Tennessee Oncology, Nashville, Tennessee, United States
H�PITAL NORD - CHU MARSEILLE, Marseille Cedex 5, , France
Chu de Toulouse Hopital Larrey Centre de Reference Des Maladies Rares de La Peau Service de Dermatol, Toulouse, , France
Zentralklinik Bad Berka Gmbh, Bad Berka, , Germany
Lungenklinik Hemer, Hemer, , Germany
Lki Lungenfachklinik Immenhausen, Immenhausen, , Germany
University Hospital Mannheim, Mannheim, , Germany
Irccs Centro Di Riferimento Oncologico, Aviano, , Italy
Istituto Tumori Giovanni Paolo Ii Irccs Ospedale Oncologico Bari, Bari, , Italy
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori, Meldola, , Italy
Azienda Ospedaliera Universitaria San Luigi Gonzaga Orbassano, Orbassano, , Italy
Azienda Ospedaliera Di Perugia - Ospedale Santa Maria Della Misericordia, Perugia, , Italy
Azienda Ospedaliero Universitaria Pisana, Pisa, , Italy
Istituto Nazionale Tumori Regina Elena Irccs, Roma, , Italy
Irccs Istituto Clinico Humanitas, Rozzano, , Italy
Complejo Hospitalario Universitario A Coruna, A Coru?a, , Spain
Hospital General Universitario Vall D Hebron, Barcelona, , Spain
Hospital Clinic de Barcelona, Barcelona, , Spain
Hospital de La Santa Creu I Sant Pau, Barcelona, , Spain
Ico Girona Hospital Universitari de Girona Dr Josep Trueta, Girona, , Spain
Hospital Universitario Ciudad de Jaen, Jaen, , Spain
Ico Institut Catala D Oncologia, L'hospitalet de Llobregat, , Spain
Hospital General Universitario Gregorio Maranon, Madrid, , Spain
Hospital Universitario Ramon Y Cajal, Madrid, , Spain
Hospital Universitario 12 de Octubre, Madrid, , Spain
Hospital Universitario de La Paz, Madrid, , Spain
Hospital Universitario Hm Sanchinarro, Madrid, , Spain
Hospital Regional Universitario de Malaga, Malaga, , Spain
Hospital Universitario Virgen Macarena, Sevilla, , Spain
Hospital Universitario Miguel Servet, Zaragoza, , Spain
Contact Details
Name: Luisa Veronese, MD
Affiliation: Incyte Corporation
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
